| Keywords: |
cancer survival; treatment outcome; treatment response; disease-free survival; survival rate; cisplatin; patient selection; cancer adjuvant therapy; cancer patient; chemotherapy, adjuvant; neoadjuvant therapy; cancer staging; lymph node metastasis; lymphatic metastasis; neoplasm staging; laparoscopy; cancer grading; lymph node excision; reproducibility of results; neoplasm recurrence, local; risk factors; editorial; necrosis; kidney neoplasms; nephrectomy; high risk patient; time factors; risk assessment; urothelium; cystectomy; nephroureterectomy; carcinoma; glomerulus filtration rate; ureteral neoplasms; neoplasm invasiveness; ureter; kidney pelvis; risk reduction; urinary tract carcinoma; recurrence free survival; tumor necrosis
|
